ArticleJournal of experimental & clinical cancer research : CR2017

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.

Silvia La Monica et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.